BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 31 newly-hired employees stock options to purchase an aggregate of 213,500 shares, and restricted stock units covering an aggregate of 24,700 shares, of BioCryst common stock.

Trevena, Inc. announced that Carrie Bourdow, President & CEO, will present a corporate overview at the BIO CEO & Investor Conference being held from February 14th - 17th, 2022.

Voyager Therapeutics, Inc. announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D. to its Board of Directors, effective February 7, and a newly formed Executive Committee of the Board consisting of Dr. Sandrock, Michael Higgins, interim chief executive officer and Board Chairman, and Glenn Pierce, M.D., Ph.D., interim chief scientific officer and Board member.

Mersana Therapeutics, Inc. announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover novel ADCs for three targets.

ProMIS Neurosciences, Inc. announced that it has appointed Drs. Guy Rouleau and Alain Dagher to its scientific advisory board.

Pardes Biosciences, Inc. announced that its Investigational New Drug application for PBI-0451 has been cleared by the United States Food and Drug Administration.

CareDx, Inc. announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the Raymond James 43rd Annual Institutional Investors Conference.

Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended December 31, 2021 on Wednesday, February 9, 2022.

Freeline Therapeutics Holdings plc announced the expansion of its executive leadership team with the appointment of Henning R. Stennicke, PhD, as Chief Scientific Officer.

Novavax, Inc. announced that the Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorization for Nuvaxovid™ COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older in Great Britain.